Anti-carbamylated protein antibodies and the risk for arthritis
AssigneeAcademisch Ziekenhuis Leiden (H.O.D.N. Lumc)
InventorsLeendert Adrianus Trouw, Reinaldus Everardus Maria Toes, Thomas Willem Johannes Huizinga, Petrus Antonius van Veelen, Anthony Cerami, Jing Shi
Life of this patent
Estimating the term…
Abstract
Antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-CarP) for the classification of individuals suffering from, or at risk of suffering from, arthritis.
Claims15
A method for providing a prognosis of severity of arthritis in a subject suffering from arthritis, the method comprising
- detecting the presence or absence of an anti-carbamylated protein (anti-CarP) antibody in a sample comprising a body fluid obtained from blood or a joint of the subject by contacting said sample with a carbamylated fetal calf serum (Ca-FCS), or carbamylated fibrinogen (Ca-Fib), or a peptide selected from the group consisting of the odd numbered SEQ ID NOs:
- 5-215,
- wherein the presence of the anti-CarP antibody in the sample indicates a risk of a more severe progression of the arthritis in the subject.
The method of 8, wherein detecting the presence or absence of the anti-citrullinated protein antibody (ACPA) is performed by contacting the same with a citrullinated protein or peptide.
Dependencies are inferred from the claim text.